Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.